United States Genetic Testing Market Size, Trends and Forecast by Type, Technology, Application, and Region, 2026-2034

The United States genetic testing market reached USD 5.89 Billion in 2025 and is projected to reach USD 15.33 Billion by 2034, exhibiting a growth rate (CAGR) of 10.87% during 2026-2034. The us genetic testing market is driven by rising prevalence of chronic and genetic diseases, notable advancements in next-generation sequencing (NGS) technology, growing consumer interest in direct-to-consumer (DTC) testing, a growing focus on precision and personalized medicine, and growing oncology diagnostics applications.

Cancer Diagnosis dominates the application segment at 42.8% in 2025, driven by BRCA screening and tumor profiling in oncology. Molecular Testing leads technology at 58.7%, underpinned by rapid NGS platform adoption. The South region leads regionally at 36.8%, anchored by dense healthcare infrastructure across Texas, Florida, and Georgia.

Market Snapshot

The market expanded from an estimated USD 3.52 Billion in 2020 to USD 5.89 Billion in 2025, supported by accelerating NGS adoption and growing insurance coverage for genetic diagnostics. The market is anchored at an estimated USD 9.87 Billion in 2030 and is projected to reach USD 15.33 Billion by 2034, with AI-powered diagnostics and liquid biopsy driving the sustained growth trajectory.

To get more information on this market, Request Sample

Molecular Testing and Cancer Diagnosis are set to grow fastest through 2034, outpacing the overall market CAGR of 10.87% as next-generation sequencing costs continue declining and companion diagnostic mandates expand. The South and West regions also grow above the market average as biotech investment and healthcare infrastructure continue to scale.

The United States genetic testing market reached USD 5.89 Billion in 2025, representing the world's largest single-country genetic diagnostics market, underpinned by fundamental strength in NGS technology, oncology companion diagnostics, and a growing consumer genomics ecosystem. Genetic testing in the United States performs a role extending well beyond clinical diagnosis, functioning as a preventive health tool, pharmacogenomic guide, and consumer wellness product across a broad, multi-application market. The market is projected to reach USD 15.33 Billion by 2034.

Molecular Testing at 58.7% dominates by capturing the rapidly expanding NGS-powered segment that enables comprehensive multi-gene panels for oncology, rare disease, and pharmacogenomics in a single workflow. Cancer Diagnosis at 42.8% leads through BRCA testing and tumor mutational burden analysis. The South at 36.8% leads nationally through dense hospital networks and high chronic disease prevalence driving diagnostic demand.

Key Market Insights

Key Analytical Observations Supporting the Above Data:

• Molecular Testing at 58.7%: This segment dominates as NGS technology dramatically reduces per-test costs, enabling broad clinical deployment across cancer, rare disease, and pharmacogenomics. Its compatibility with multi-gene panels and whole-genome sequencing workflows reinforces segment leadership. Rapid throughput improvements and the proliferation of FDA-cleared NGS-based companion diagnostics further sustain its dominant and expanding market position.
• Cancer Diagnosis at 42.8%: The oncology application leads due to BRCA1/2 testing, tumor profiling, and companion diagnostic requirements linked to FDA-approved targeted therapies. Growing adoption of liquid biopsy and circulating tumor DNA for non-invasive cancer monitoring adds incremental volume. Expanded genetic counseling integration and payer coverage for hereditary cancer panels continue to deepen this segment's market penetration across hospital and clinic settings.
• South at 36.8%: Texas, Florida, and Georgia anchor this region through major hospital networks, rising chronic disease burden, and growing biotech investment supporting genetic diagnostics infrastructure. Expanding insurance coverage for genetic tests and an aging population driving predictive testing demand amplify regional growth within the united states genetic testing market Size landscape.

The United States genetic testing market encompasses diagnostic, predictive, and consumer genomics services utilizing DNA sequencing, chromosomal analysis, and biochemical assays. Applications span oncology, rare disease, cardiovascular, reproductive, pharmacogenomic, and direct-to-consumer wellness testing, covering clinical laboratory and consumer market segments.

The ecosystem integrates biotech innovators, laboratory service providers, healthcare networks, and regulatory bodies including the FDA and CMS. Federal reimbursement policies and NGS regulatory pathways shape the market's structural growth dynamics.

To evaluate market opportunities, Request Sample

Market Drivers

• Rising Prevalence of Genetic and Chronic Diseases: Increasing incidence of hereditary cancers, cardiovascular conditions, and rare genetic disorders directly expands demand for diagnostic and predictive genetic testing across clinical specialties. Growing physician adoption of genetic screening protocols in oncology, cardiology, and reproductive medicine strengthens test volumes. Multi-gene panel ordering per patient is rising as clinical guidelines increasingly mandate genetic workups for hereditary disease risk assessment.
• Advances in NGS Technology and Cost Reduction: Next-generation sequencing has reduced whole-genome sequencing costs from millions of dollars to under USD 1,000, enabling broad clinical and consumer deployment at commercially viable price points. Rapid throughput improvements and panel expansion allow laboratories to offer comprehensive multi-gene tests faster and more affordably than ever before. Continued cost deflation across NGS instruments, reagents, and bioinformatics is expected to sustain the United States genetic testing market Growth through the forecast period.
• Growing Demand for Personalized Medicine: Precision medicine approaches require genetic profiling to guide treatment selection, particularly in oncology and pharmacogenomics, driving sustained multi-test ordering per patient. Payers and health systems are progressively embedding genetic testing into care pathways, expanding the addressable market across clinical specialties and primary care. FDA approvals of genetically guided therapies with companion diagnostic requirements support sustained mandatory testing volume.
• Expanding DTC Genetic Testing Awareness: Consumer-facing platforms dramatically increased public awareness of genetic health information, expanding testing demand well beyond clinical settings into the general consumer market. DTC platforms broadening from ancestry into health risk, pharmacogenomics, and wellness insights are widening the addressable market to millions of non-clinical consumers annually.

Market Restraints

• High Cost of Advanced Genetic Tests: Despite NGS cost reductions, comprehensive multi-gene panels and whole-genome sequencing remain expensive for uninsured or underinsured patients, limiting broad population-level access. Inconsistent payer coverage policies across commercial insurers and Medicare create access barriers that constrain adoption in cost-sensitive patient populations and lower-income demographics across the us genetic testing market.
• Data Privacy and Ethical Concerns: Genetic information is uniquely sensitive, raising patient concerns about data security, insurer discrimination, and third-party data sharing by genomics companies. Regulatory uncertainty around data governance frameworks and genetic information non-discrimination protections creates barriers to DTC adoption. Ethical debates around predictive testing for life insurance and employment continue to limit consumer willingness to share genomic data with commercial genomics platforms.
• Complex Regulatory Approval Processes: FDA oversight of laboratory-developed tests (LDTs) and evolving regulatory frameworks create compliance costs and uncertain approval timelines that constrain new test launches. Changing regulatory requirements for LDTs introduce risk for smaller specialized laboratories with limited compliance infrastructure and resources. Lengthy clinical validation requirements and complex reimbursement coding processes add time-to-market delays that slow adoption of innovative genetic testing technologies into routine care.

Market Opportunities

• AI-Powered Genomic Diagnostics: Artificial intelligence and machine learning platforms are improving variant interpretation accuracy, enabling faster clinical reporting, and identifying novel disease associations across large genomic datasets. AI-driven diagnostic tools reduce pathologist workload and interpretation variability while enabling scalable high-volume clinical NGS workflows. Healthcare systems and laboratory networks are actively investing in AI-genomics integration as a core operational priority.
• Liquid Biopsy and Non-Invasive Testing: Cell-free DNA and circulating tumor DNA technologies enable cancer screening and treatment monitoring through blood draws, significantly reducing procedural barriers to early detection. Expanding FDA-cleared liquid biopsy applications represent a structurally growing opportunity for oncology diagnostic providers and testing laboratories. The non-invasive nature of liquid biopsy supports broader integration into routine cancer screening programs nationwide.

Market Challenges

• Reimbursement Uncertainty: Coverage policies for newer genetic tests remain inconsistent across commercial payers and Medicare, creating revenue uncertainty for laboratory providers planning commercial launches. Prolonged coverage determination processes and frequent coding changes add administrative burden that disproportionately affects smaller independent laboratories across the united states genetic testing market.
• Workforce and Interpretation Gaps: Demand for genetic counselors and clinical genomicists significantly exceeds available supply, creating interpretation bottlenecks that slow test adoption in clinical settings. Insufficient training infrastructure for primary care physicians in genomic medicine limits the integration of genetic testing into routine preventive care pathways. Growing test volumes and panel complexity further strain clinical genetics workforce capacity.

1. Liquid Biopsy and Cell-Free DNA Adoption

Liquid biopsy tests using circulating tumor DNA are transitioning from research use to routine clinical oncology practice, enabling non-invasive cancer detection, treatment monitoring, and minimal residual disease assessment. FDA approvals for blood-based cancer screening are expanding clinical utility well beyond traditional tissue biopsy settings.

2. AI and Machine Learning in Variant Interpretation

Artificial intelligence platforms are significantly improving the speed and accuracy of genomic variant pathogenicity classification, reducing expert workload and enabling scalable clinical reporting at high volume. AI-assisted tools are being embedded into laboratory information systems across major reference laboratories as a core workflow component.

3. Pharmacogenomics Integration into Clinical Care

Pharmacogenomic testing, which guides drug selection and dosing based on patient genetic profiles, is being embedded into electronic health record systems and hospital formulary protocols for psychiatry, oncology, and primary care specialties. This integration drives multi-test ordering per patient and strengthens the clinical value proposition for genetic platforms.

4. DTC Platform Expansion into Health and Wellness

Direct-to-consumer platforms are broadening from ancestry into carrier screening, health predisposition, and polygenic risk scores, forming partnerships with healthcare systems to bridge consumer-generated genetic data into clinical workflows. This consumer-to-clinical pipeline is creating a new scalable patient acquisition model for the broader genetic testing ecosystem.

The United States genetic testing value chain spans R&D and scientific discovery, raw material and reagent sourcing, test kit and instrument manufacturing, laboratory processing and sequencing, clinical reporting and delivery, and data analysis and interpretation. Each stage is shaped by regulatory compliance requirements, reimbursement policies, and technology performance standards that define commercial viability.

Quality and safety oversight is embedded throughout the chain, with FDA clearance requirements shaping product development timelines and CMS coverage policies determining test adoption at the laboratory and clinical delivery stages.

Next-Generation Sequencing (NGS)

NGS represents the most transformative technology in genetic testing, enabling rapid and cost-effective sequencing of entire genomes or targeted gene panels at clinical scale. Its compatibility with cancer profiling, rare disease diagnosis, and pharmacogenomics makes it the primary growth engine across the Molecular Testing segment and the broader market.

CRISPR-Based Diagnostic Platforms

CRISPR-based diagnostic tools including SHERLOCK and DETECTR are emerging as highly sensitive and specific molecular detection methods for genetic mutations and pathogens. Their potential for point-of-care deployment and rapid detection is attracting significant R&D investment within the clinical and consumer diagnostics sectors.

AI-Assisted Genomic Analysis

Machine learning algorithms trained on large genomic datasets are enabling automated variant pathogenicity classification and population-level risk prediction with increasing clinical accuracy. Integration into laboratory information systems is improving diagnostic turnaround times and reducing interpretation variability across laboratory networks.

The report covers the following segments:

By Technology

Molecular Testing leads at 58.7% in 2025, driven by NGS-powered cancer, rare disease, and pharmacogenomic panels that cover hundreds of clinically relevant genes in a single workflow. This segment's growth outpaces the overall united states genetic testing market Trends as test panels expand and sequencing costs continue to fall.

To access detailed market analysis, Request Sample

Cytogenetic Testing and Chromosome Analysis holds 23.6%, anchored by karyotyping and chromosomal microarray applications for prenatal diagnosis, hematologic malignancies, and constitutional disorders. Biochemical Testing at 17.7% encompasses metabolic disorder screening, particularly newborn screening panels mandated across all U.S. states.

By Application

Cancer Diagnosis leads at 42.8% in 2025, anchored by hereditary cancer syndrome testing, tumor mutational burden analysis, and companion diagnostic requirements for FDA-approved targeted oncology therapies. This segment's clinical centrality reflects the FDA's growing approval pipeline of genetically-guided cancer treatment protocols.

Genetic Disease Diagnosis at 28.7% spans rare Mendelian disorders, prenatal and newborn screening, and carrier testing for heritable conditions. Cardiovascular Disease Diagnosis at 17.6% covers familial hypercholesterolemia, inherited arrhythmias, and cardiomyopathy panels. Others, including pharmacogenomics and ancestry testing, account for 10.9%.

Regional Market Insights

The South at 36.8% leads through the healthcare infrastructure concentration in Texas, Florida, and Georgia, combined with high prevalence of chronic diseases—diabetes, cardiovascular conditions, and cancers—that drive predictive and diagnostic genetic testing demand across clinical and preventive care settings.

The West at 25.7% is anchored by California's dense biotech and life sciences ecosystem, including Silicon Valley-based genomics innovators and consumer DTC platforms. The Northeast at 19.6% benefits from leading academic medical centers in Boston, New York, and Philadelphia, with high specialist density and strong insurance coverage. The Midwest at 17.9% reflects steady growth through clinical genomics integration in major hospital systems across Illinois, Minnesota, and Ohio.

The United States genetic testing market competitive landscape is highly competitive, with global and domestic players vying for market leadership. It features three distinct tiers: large integrated diagnostics conglomerates with national laboratory networks, specialized oncology and rare-disease genetics firms, and consumer-facing DTC genomics platforms with large proprietary genetic databases.

Key players include Quest Diagnostics Incorporated, Labcorp., Myriad Genetics, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., and others.

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated is the largest U.S. clinical laboratory company, with a national network of patient service centers and high-throughput processing capabilities supporting genetic testing across oncology, reproductive health, and pharmacogenomics.

• Key Products: Hereditary cancer panels, non-invasive prenatal testing (NIPT), pharmacogenomics, cytogenetics, and molecular oncology panels delivered through a national clinical network.
• Recent Development: In September 2025, Quest Diagnostics introduced an advanced pharmacogenomic (PGx) laboratory testing service in collaboration with Coriell Life Sciences to help clinicians use patients’ genetic information to guide medication selection and dosing. The offering evaluates 17 genes and 4 HLA alleles associated with clinically actionable gene–drug interactions and provides information on predicted drug response.
• Strategic Focus: Expanding the genetic test menu through technology partnerships, AI-powered reporting integration, and value-based care pathway embedding across hospital and payer networks. Quest is investing in DTC testing expansion, laboratory automation, and digital health platforms to capture growth across clinical and consumer segments.

Myriad Genetics, Inc.

Myriad Genetics, Inc. is a precision medicine company that pioneered hereditary cancer genetic testing in the United States with the BRACAnalysis test, holding a leading position in BRCA testing and hereditary cancer panel diagnostics. The company also operates GeneSight, a leading pharmacogenomics platform, and has expanded into prenatal and cardiovascular genetic testing through strategic acquisitions.

• Key Products: BRACAnalysis CDx, MyRisk hereditary cancer panel, GeneSight pharmacogenomics, Prequel prenatal screening, and RiskScore polygenic risk assessment tools for breast cancer and melanoma.
• Strategic Focus: Expanding pharmacogenomics into mainstream psychiatry and primary care while defending hereditary cancer panel market leadership against growing NGS panel competition. Myriad is broadening its companion diagnostic partnerships with biopharmaceutical companies and investing in polygenic risk score product development to capture emerging preventive medicine market opportunities and sustain long-term revenue diversification.

The United States genetic testing market is moderately concentrated at the integrated diagnostics level, with the key players commanding a leading share of routine clinical genetic test volume. Market concentration is expected to remain broadly stable through 2034.

Highest Growth Segments

Cancer Diagnosis (~13.1% CAGR) and Molecular Testing (~12.4% CAGR) represent the highest-growth investment vectors through 2034, both outpacing the overall market CAGR of 10.87% as companion diagnostics proliferate and NGS panel adoption accelerates across oncology centers and reference laboratories nationally.

Emerging Investment Opportunities

AI-powered diagnostic platforms and liquid biopsy cancer screening represent the market's most structurally attractive emerging themes, supported by regulatory momentum and favorable reimbursement signals from CMS and commercial payers.

Investment Themes

• AI and Bioinformatics Platform Investment: Automating variant interpretation and clinical report generation offers significant margin improvement and capacity scaling opportunities for laboratory operators facing high-volume NGS workflow demands. Early-mover advantages in AI-genomics integration are expected to compound as training datasets expand and model accuracy improves.
• DTC-to-Clinical Pipeline Development: Building integrated platforms that convert consumer-generated genetic data into physician-ordered diagnostic follow-up creates a scalable patient acquisition and recurring test volume model with lower customer acquisition costs than traditional clinical marketing approaches.

The United States genetic testing market is projected to grow from USD 5.89 Billion in 2025 to USD 15.33 Billion by 2034, delivering a steady 10.87% CAGR over the forecast period. The market's anchor value of an estimated USD 9.87 Billion in 2030 represents a diagnostics industry in accelerating structural expansion, with NGS cost deflation, AI-assisted reporting, and liquid biopsy adoption anchoring growth even as traditional genetic disease testing matures.

AI-powered genomic diagnostics and whole-genome sequencing are expected to achieve wider mainstream clinical adoption by 2030, while pharmacogenomic integration into electronic health records will drive multi-test ordering per patient. Three forces will define market growth through 2034: expansion of oncology companion diagnostics, integration of genetic testing into preventive care, and maturation of AI-assisted clinical genomics.

Primary Research

Primary research comprised structured interviews with laboratory executives, oncology geneticists, genetic counselors, payer policy specialists, and industry association representatives, providing first-hand insight into clinical adoption trends, pricing dynamics, and competitive positioning across the value chain.

Secondary Research

Secondary research encompassed company annual reports, FDA approval databases, CMS reimbursement schedules, NIH funding disclosures, industry publications, and peer-reviewed genomics literature, cross-verified across multiple independent sources to ensure data reliability and analytical accuracy.

Forecasting Models

Market revenue forecasts were developed using a bottom-up test-volume model incorporating disease prevalence trends, clinical guideline adoption rates, payer coverage expansion forecasts, and technology cost curve projections for NGS and downstream analytical platforms across all segments and regions.

United States Genetic Testing Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States genetic testing market from 2020-2034.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the United States genetic testing market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States genetic testing industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.